Health-related quality of life (HRQoL) of pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase III KEYNOTE-590 study.

Wasat Mansoor,As Kulkarni,Ken Kato,Jong Mu Sun,Manish A. Shah,Peter C. Enzinger,Antoine Adenis,Toshihiko Doi,Takashi Kojima,Jean-Philippe Metges,Zhigang Li,Sung-Bae Kim,Byoung Chul Cho,Patrapim Sunpaweravong,Maria Alsina,Eray Goekkurt,Shailaja Suryawanshi,Josephine M. Norquist,Sukrut Shah,Lin Shen

Health-related quality of life (HRQoL) of pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase III KEYNOTE-590 study.

2021

168Background: In the randomized, international, double-blind, placebo-controlled KEYNOTE-590 (NCT03189719) study, pembrolizumab (pembro) + chemotherapy (chemo) provided statistically significant a...

Keywords:

Medicine
Internal medicine
first line therapy
Oncology
health related quality of life
Pembrolizumab
in patient
advanced esophageal cancer
Chemotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations